New cream trial targets painful rash from cancer drugs
NCT ID NCT06399029
Summary
This study is testing a cream called ruxolitinib to see if it can safely and effectively treat skin rashes that develop as a side effect of a common cancer immunotherapy (anti-PD1). The cream is already approved for other skin conditions. Researchers will enroll about 20 adult patients who developed this specific rash during their cancer treatment to measure how well the cream reduces the rash and improves quality of life over 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXANTHEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University hospital Zürich, Department Dermatology
RECRUITINGZurich, 8091, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.